Table 1.
Characteristic | No. (%) |
---|---|
Total |
93 (100.0) |
Median age (range) |
63 (34 – 79) |
Sex | |
Men |
79 (84.9%) |
Women |
14 (15.1%) |
Pathological T stage | |
T1* |
4 (4.3%) |
T2 |
15 (16.1%) |
T3 |
52 (55.9%) |
T4 |
22 (23.7%) |
Pathological N stage | |
Node negative |
61 (65.6%) |
Node positive |
32 (34.4%) |
Histologic type | |
Squamous differentiation |
11 (11.8%) |
Other types |
82 (88.2%) |
Pathological grade† | |
G2 |
10 (10.8%) |
G3 |
83 (89.2%) |
ERCC1 expression | |
Positive |
54 (58.1%) |
Negative |
39 (41.9%) |
Adjuvant chemotherapy (gemcitabine plus cisplatin) | |
Yes |
57 (61.3%) |
4 cycles |
24 (25.8%) |
3 cycles |
28 (30.1%) |
2 cycles |
4 (4.3%) |
1 cycle |
1 (1.1%) |
No | 36 (38.7%) |
*all patients have metastatic lymph nodes. † 1973 WHO grading.